TiumBio Overview
- Year Founded
-
2016
- Status
-
Public
- Employees
-
70
- Stock Symbol
-
321550
- Investments
-
6
- Share Price
-
$2.76
- (As of Thursday Closing)
TiumBio General Information
Description
TiumBio Co Ltd is a Biopharmaceutical company. It is engaged in research and development of rare and intractable diseases. The company's products are in pipeline. It offers products such as Idiopathic pulmonary fibrosis therapies, immune chemotherapy, endometriosis therapies, hemophilia.
Contact Information
Website
www.tiumbio.comCorporate Office
- 6th Floor, Pangyo IT Center
- 30 Changup-ro 40 beon-gil, Sujeong-gu, Republic of Korea
- Seongnam, Gyeonggi 13449
- South Korea
Corporate Office
- 6th Floor, Pangyo IT Center
- 30 Changup-ro 40 beon-gil, Sujeong-gu, Republic of Korea
- Seongnam, Gyeonggi 13449
- South Korea
TiumBio Stock Performance
As of 12-Nov-2026, TiumBio’s stock price is $2.76. Its current market cap is $82.8M with 30M shares.
(As of Thursday Closing)
| Stock Price | Previous Close | 52 wk Range | Market Cap | Shares | Average Volume | EPS |
|---|---|---|---|---|---|---|
| $2.76 | $2.77 | $2.22 - $9.20 | $82.8M | 30M | 119K | -$0.41 |
TiumBio Financials Summary
As of 30-Jun-2026, TiumBio has a trailing 12-month revenue of $10.3M.
|
In Thousands, USD |
TTM 30-Jun-2026 | FY 2025 31-Dec-2025 | FY 2024 31-Dec-2024 | FY 2023 31-Dec-2023 |
|---|---|---|---|---|
| EV | 74,676 | 106,322 | 80,302 | 201,670 |
| Revenue | 10,334 | 8,635 | 4,978 | 3,747 |
| EBITDA | (6,971) | (7,162) | (11,862) | (11,119) |
| Net Income | (11,791) | (12,199) | (15,130) | (13,699) |
| Total Assets | 58,990 | 68,440 | 72,845 | 92,766 |
| Total Debt | 18,510 | 22,328 | 20,489 | 22,504 |
TiumBio Valuation & Funding
| Deal Type | Date | Amount | Valuation/ EBITDA |
Post-Val | Status | Debt |
|---|
TiumBio Comparisons
Industry
Financing
Details
TiumBio Competitors (3)
One of TiumBio’s 3 competitors is MedPacto, a Formerly VC-backed company based in Seoul, South Korea.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| MedPacto | Formerly VC-backed | Seoul, South Korea | ||||
| ABL Bio | Formerly VC-backed | Seoul, South Korea | ||||
| Genome & Company | Formerly VC-backed | Seongnam, South Korea |
TiumBio Patents
TiumBio Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026054435-A1 | Anti-ne antibody and pharmaceutical composition for preventing or treating ne hyperactivation-related diseases comprising same | Pending | 05-Sep-2024 | ||
| WO-2025230335-A1 | Pharmaceutical composition for treating or preventing estrogen-dependent diseases | Pending | 03-May-2024 | ||
| WO-2025014200-A1 | Compound and pharmaceutical composition comprising same | Inactive | 07-Jul-2023 | ||
| WO-2024151112-A1 | Pyrazolopyrimidine derivative as cyclin-dependent kinase 9 inhibitor | Inactive | 11-Jan-2023 | ||
| CA-3227334-A1 | Pharmaceutical composition for preventing or treating tumor, and use thereof | Pending | 28-Jul-2021 | A61K31/498 |
TiumBio Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
TiumBio Investors
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|
TiumBio Investments & Acquisitions (6)
TiumBio’s most recent deal was a Merger/Acquisition with Petraon for . The deal was made on 27-Dec-2024.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Petraon | 27-Dec-2024 | Merger/Acquisition | Personal Products | ||
| SK Bioscience | 20-Dec-2023 | Secondary Transaction - Private | Drug Discovery | ||
| Frontier Maru (Research and Development and Office Center in Seoul, South Korea) | 28-Apr-2023 | Corporate Asset Purchase | Buildings and Property | ||
| SK Plasma | 06-Aug-2021 | Later Stage VC | Pharmaceuticals | ||
| MEPSGEN | 01-Aug-2021 | Early Stage VC | Drug Discovery |
TiumBio ESG
Peers Analysis
Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.
Global
Covered Companies
Rank
Percentile
Pharmaceuticals
Industry
Rank
Percentile
Pharmaceuticals
Subindustry
Rank
Percentile
TiumBio Exits (1)
TiumBio’s most recent exit was on 06-Aug-2021 from SK Plasma. The exit was categorized as with 3 buyers.
| Company Name | Exit Date | Exit Type | Exit Size | Status | Buyers |
|---|---|---|---|---|---|
| SK Plasma | 06-Aug-2021 | Completed |
|
TiumBio Affiliates
Subsidiaries (1)
| Name | Industry | Location | Year Founded |
|---|---|---|---|
| Petraon | Gwangju-si, South Korea | 2014 |
TiumBio FAQs
-
When was TiumBio founded?
TiumBio was founded in 2016.
-
Where is TiumBio headquartered?
TiumBio is headquartered in Seongnam, South Korea.
-
What is the size of TiumBio?
TiumBio has 70 total employees.
-
What industry is TiumBio in?
TiumBio’s primary industry is Biotechnology.
-
Is TiumBio a private or public company?
TiumBio is a Public company.
-
What is TiumBio’s stock symbol?
The ticker symbol for TiumBio is 321550.
-
What is the current stock price of TiumBio?
As of 12-Nov-2026 the stock price of TiumBio is $2.76.
-
What is the current market cap of TiumBio?
The current market capitalization of TiumBio is $82.8M.
-
What is TiumBio’s current revenue?
The trailing twelve month revenue for TiumBio is $10.3M.
-
Who are TiumBio’s competitors?
MedPacto, ABL Bio, and Genome & Company are competitors of TiumBio.
-
What is TiumBio’s annual earnings per share (EPS)?
TiumBio’s EPS for 12 months was -$0.41.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
